Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;3(2):107-11.
doi: 10.4103/2278-330X.130443.

Evaluation of protective effect of myricetin, a bioflavonoid in dimethyl benzanthracene-induced breast cancer in female Wistar rats

J K Jayakumar  1 , P Nirmala  2 , B A Praveen Kumar  3 , Ashok P Kumar  4
Affiliations

Evaluation of protective effect of myricetin, a bioflavonoid in dimethyl benzanthracene-induced breast cancer in female Wistar rats

J K Jayakumar et al. South Asian J Cancer. 2014 Apr.

Abstract

Background: Breast cancer is one of the most common cancers worldwide. Alarmingly, the incidence of breast cancer is rising rapidly in India.

Aim: The present research was focused to assess the role of myricetin; a bioflavonoid in 7,12-dimethylbenzanthracene (DMBA)-induced breast cancer in female Wistar rats.

Materials and methods: A total of 36 female Wistar rats (total 6 groups, n = 6 per group) 6 - 8 weeks old, weighing 150 gm were used in the study. DMBA was given at the dose of 7.5 mg/kg subcutaneously in the mammary region once a week for 4 consecutive weeks in group 2. Vincristine was given in the dose of 500 μg/kg intraperitonially every week for 4 consecutive weeks in group 3. Myricetin was given orally in a dose of 50, 100, and 200 mg/kg in group 4, 5, and 6 respectively. The statistical significance of the data was determined using one way analysis of variance and Duncan's multiple range test.

Results: The result showed that myricetin increased the antioxidant levels in plasma, erythrocyte lysate, and breast tissue and was effective in preventing the oxidative damage induced by the carcinogen DMBA. Myricetin 50, 100, and 200 mg/kg/oral for 120 days treated animal resulted comparable results to that of standard vincristine and control groups.

Conclusions: Myricetin was found to be either equieffective or more effective than vincristine in all the parameters studied. Myricetin proved the capacity of flavonols to act as antioxidant in cells represents a potential treatment in the field of oncology.

Keywords: 7,12-dimethylbenzanthracene; Anti oxidants; breast cancer; dimethyl benzanthracene; myricetin; vincristine.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None declared.

Figures

Figure 1
Figure 1
Macroscopic changes
Figure 2
Figure 2
Ulcer produced in the rat treated with 7,12-dimethyl benzanthracene
Figure 3
Figure 3
Tumors produced in the rat treated with 7,12-dimethyl benzanthracene
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Reddy NS, Nirmala P, Chidambaram N, Kumar PA. Quercetin in dimethyl benzanthracene induced breast cancer in rats. Am J Pharmacol Toxicol. 2012;7:68–72.
    1. Notani PN. Global variation in cancer incidence and mortality. Curr Sci. 2001;81:465–74.
    1. Sariego J. Breast cancer in the young patient. Am Surg. 2010;76:1397–400. - PubMed
    1. Miyata M, Furukawa M, Takahashi K, Gonzalez FJ, Yamazoe Y. Mechanism of 7,12-Dimethylbenz [a] anthracene-induced immunotoxicity: Role of metabolic activation at the target organ. Jpn J Pharmacol. 2001;86:302–9. - PubMed
    1. Yang SK, Dower WV. Metabolic pathways of 7,12-dimethylbenz [a] anthracene in hepatic microsomes. Proc Natl Acad Sci U S A. 1975;72:2601–5. - PMC - PubMed